Table 1.
Induction of NK‐cell‐mediated cytotoxicity in PBMC treated with dSLIM® or ProMune®
| Specific cytotoxicity a | Activator | μM b | Mean c | SEM | n |
|---|---|---|---|---|---|
| Effector:target: 10:1 | ProMune® | 0.2 | 34.7 | 3.4 | 4 |
| ProMune® | 3 | 5.8 | 3.6 | 8 | |
| dSLIM® | 3 | 26.6 | 3.8 | 8 | |
| dSLIM® | 20 | 21.2 | 11 | 4 | |
| Effector:target: 5:1 | ProMune® | 0.2 | 39.7 | 1.7 | 4 |
| ProMune® | 3 | 2.1 | 2.1. | 6 | |
| dSLIM® | 3 | 28.3 | 8.8 | 6 | |
| dSLIM® | 20 | 36.5 | 6.9 | 4 |
After 48 h stimulation with the indicated TLR9 agonist, PBMC were co‐cultured with the indicated proportions of Dil‐labeled Jurkat cells as targets for 4 h. After staining with 7‐AAD, specific cytotoxicity was estimated based on the frequencies of 7‐AAD positive target cells as described in Materials and Methods section.
PBMC were treated with dSLIM® or ProMune® at the indicated concentrations; 0.2 μM ProMune® and 20 μM dSLIM® were chosen according to the maximal activation of NK cells detected in PBMC under these conditions as shown in Figure 2.
Means were derived from the calculated specific cytotoxicities after correction for the spontaneous cytotoxicity determined in the negative controls (PBMCs incubated in complete medium) and normalization to the positive controls (PBMC treated with 2000 U/mL recombinant IL‐2).